Assessment Of the Outcome of Remdesivir in The Treatment of Covid-19 Patients: A Retrospective Observational Study

Background Coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a global pandemic by the World Health Organisation (WHO) in March 2020. Amidst the evolving therapeutic landscape, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorisation (EUA) for Remdesivir—an antiviral agent—for the treatment of hospitalised patients with severe COVID-19. Objective: To evaluate clinical outcomes associated with Remdesivir therapy in hospitalised COVID-19 patients, with a focus on recovery and mortality rates. Methodology-Following institutional approvals, a retrospective analysis of medical records was conducted at a tertiary care teaching hospital. Data were collected for confirmed COVID-19 patients who received Remdesivir. Variables assessed included patient comorbidities, details of Remdesivir therapy, vital signs at admission and discharge, inflammatory markers, radiological findings, duration of recovery, and clinical outcome (recovered or deceased). Results: The study included 400 patients. Of these, 214 patients (53.5%) completed the full 5-day course of Remdesivir, with a recovery rate of 93.9%. Among those who received a partial course (2–3 days), the recovery rate was 82.2%. The difference in outcomes between complete and incomplete treatment groups was statistically significant (p = 0.037). Conclusion: This retrospective study demonstrates that completion of the full 5-day course of Remdesivir therapy is associated with significantly improved clinical outcomes in hospitalised COVID-19 patients. The overall recovery rate in the cohort was 88.5%.